These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36765740)

  • 1. Prevalence of Sarcopenia and Impact on Survival in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours.
    Clement DSVM; Leerdam MEV; de Jong S; Weickert MO; Ramage JK; Tesselaar MET; Srirajaskanthan R
    Cancers (Basel); 2023 Jan; 15(3):. PubMed ID: 36765740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The global leadership into malnutrition criteria reveals a high percentage of malnutrition which influences overall survival in patients with gastroenteropancreatic neuroendocrine tumours.
    Clement DSVM; van Leerdam ME; Tesselaar MET; Cananea E; Martin W; Weickert MO; Sarker D; Ramage JK; Srirajaskanthan R
    J Neuroendocrinol; 2024 Apr; 36(4):e13376. PubMed ID: 38389192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours.
    Chiramel J; Almond R; Slagter A; Khan A; Wang X; Lim KHJ; Frizziero M; Chakrabarty B; Minicozzi A; Lamarca A; Mansoor W; Hubner RA; Valle JW; McNamara MG
    World J Clin Oncol; 2020 Apr; 11(4):205-216. PubMed ID: 32355642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GEP-NET radiomics: a systematic review and radiomics quality score assessment.
    Staal FCR; Aalbersberg EA; van der Velden D; Wilthagen EA; Tesselaar MET; Beets-Tan RGH; Maas M
    Eur Radiol; 2022 Oct; 32(10):7278-7294. PubMed ID: 35882634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States.
    Xu Z; Wang L; Dai S; Chen M; Li F; Sun J; Luo F
    JAMA Netw Open; 2021 Sep; 4(9):e2124750. PubMed ID: 34554237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sarcopenia and Ghrelin System in the Clinical Outcome and Prognosis of Gastroenteropancreatic Neuroendocrine Neoplasms.
    Herrera-Martínez Y; Alzas Teomiro C; León Idougourram S; Molina Puertas MJ; Calañas Continente A; Serrano Blanch R; Castaño JP; Gálvez Moreno MÁ; Gahete MD; Luque RM; Herrera-Martínez AD
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study.
    Paulson S; Ray D; Aranha S; Scales A; Wang Y; Liu E
    Oncol Ther; 2022 Dec; 10(2):463-479. PubMed ID: 36136274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study.
    Lesén E; Granfeldt D; Berthon A; Dinet J; Houchard A; Myrenfors P; Björstad Å; Björholt I; Elf AK; Johanson V
    J Cancer; 2019; 10(27):6876-6887. PubMed ID: 31839822
    [No Abstract]   [Full Text] [Related]  

  • 9. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review.
    Watson C; Tallentire CW; Ramage JK; Srirajaskanthan R; Leeuwenkamp OR; Fountain D
    World J Gastroenterol; 2020 Jul; 26(25):3686-3711. PubMed ID: 32742136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical features of the ectopic ACTH syndrome in patients with gastroenteropancreatic and thoracic neuroendocrine tumors.
    Kamp K; Alwani RA; Korpershoek E; Franssen GJ; de Herder WW; Feelders RA
    Eur J Endocrinol; 2016 Mar; 174(3):271-80. PubMed ID: 26643855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour-to-liver ratio determined by [
    Kim YI; Yoo C; Oh SJ; Lee SJ; Kang J; Hwang HS; Hong SM; Ryoo BY; Ryu JS
    EJNMMI Res; 2020 Jun; 10(1):63. PubMed ID: 32542576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.
    Khan MS; Walter T; Buchanan-Hughes A; Worthington E; Keeber L; Feuilly M; Grande E
    World J Gastroenterol; 2020 Aug; 26(30):4537-4556. PubMed ID: 32874063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Tumor Site Affects Survival in Patients with Gastroenteropancreatic and Neuroendocrine Liver Metastases.
    Tierney JF; Poirier J; Chivukula S; Pappas SG; Hertl M; Schadde E; Keutgen X
    Int J Endocrinol; 2019; 2019():9871319. PubMed ID: 30992703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Liver Metastases from Midgut Neuroendocrine Tumours: A Systematic Review and Meta-Analysis.
    Kaçmaz E; Heidsma CM; Besselink MGH; Dreijerink KMA; Klümpen HJ; Nieveen van Dijkum EJM; Engelsman AF
    J Clin Med; 2019 Mar; 8(3):. PubMed ID: 30909512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness.
    Barrea L; Altieri B; Muscogiuri G; Laudisio D; Annunziata G; Colao A; Faggiano A; Savastano S
    Nutrients; 2018 Dec; 10(12):. PubMed ID: 30513732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardio-Metabolic Indices and Metabolic Syndrome as Predictors of Clinical Severity of Gastroenteropancreatic Neuroendocrine Tumors.
    Barrea L; Muscogiuri G; Modica R; Altieri B; Pugliese G; Minotta R; Faggiano A; Colao A; Savastano S
    Front Endocrinol (Lausanne); 2021; 12():649496. PubMed ID: 33815296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 177Lu-DOTATATE therapy in patients with neuroendocrine tumours including high-grade (WHO G3) neuroendocrine tumours: response to treatment and long-term survival update.
    Demirci E; Kabasakal L; Toklu T; Ocak M; Şahin OE; Alan-Selcuk N; Araman A
    Nucl Med Commun; 2018 Aug; 39(8):789-796. PubMed ID: 29912750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigating Nutrition-Related Complications and Quality of Life in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Protocol for a Mixed-Methods Prospective Study.
    Laing E; Kiss N; Michael M; Gough K; Krishnasamy M
    JMIR Res Protoc; 2018 Dec; 7(12):e11228. PubMed ID: 30567691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.
    Kim ST; Ha SY; Lee S; Ahn S; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim KM; Park YS
    J Cancer; 2016; 7(5):484-9. PubMed ID: 26958083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.